{"id":561,"date":"2018-07-19T08:29:55","date_gmt":"2018-07-19T06:29:55","guid":{"rendered":"https:\/\/fci.health\/forschung\/"},"modified":"2023-07-28T12:32:59","modified_gmt":"2023-07-28T10:32:59","slug":"platform","status":"publish","type":"page","link":"https:\/\/fci.health\/en\/platform\/","title":{"rendered":"Platform"},"content":{"rendered":"

[vc_row full_width=”stretch_row_content_no_spaces” dhsv_background_color=”bg_brand-primary” dhsv_overflow=”vc-overflow-visible”][vc_column el_id=”ueberuns”][dhsv_vc_slider image_right=”162″ image_middle=”161″ image_left=”160″ anchor=”1″][vc_column_text css_animation=”none”]<\/p>\n

Unique Environment<\/p>\n

Molecular Mechanisms<\/p>\n

[\/vc_column_text][vc_column_text]<\/p>\n

Precision Oncology<\/p>\n

Teamspirit<\/p>\n

[\/vc_column_text][\/dhsv_vc_slider][dhsv_vc_anker type=”nav”][\/vc_column][\/vc_row][vc_row el_class=”translateY100″][vc_column offset=”vc_col-md-4″][dhsv_vc_anker type=”point” title=”Clinical Translation Programs” id=”querschnittsprogramme”][\/vc_column][vc_column offset=”vc_col-md-7″][vc_column_text]<\/p>\n

Clinical Translation Programs\u00a0are the\u00a0Strategic Core<\/strong><\/span>\u00a0of FCI.<\/p>\n

[\/vc_column_text][\/vc_column][vc_column offset=”vc_col-md-1″][\/vc_column][\/vc_row][vc_row dhsv_margin_top=”vc-margin-top-medium” dhsv_margin_bottom=”vc-margin-bottom-medium”][vc_column][dhsv_vc_forschungsbereiche headtitle=”Research in FCI” elements=”%5B%7B%22line1%22%3A%22Clinical%20Translation%20Programs%22%2C%22line2%22%3A%22Strategic%20Core%20of%20FCI%22%2C%22text%22%3A%22Multidisciplinary%20teams%20consisting%20of%20clinicians%2C%20tumor%20biologists%2C%20biochemists%2C%20chemists%20and%20bioinformaticians%20work%20together%20in%20these%20interdisciplinary%20research%20projects.%20The%20teams%20rely%20on%20the%20technology%20platforms%20provided%20by%20the%20five%20research%20areas.%20%22%2C%22link%22%3A%22url%3Ahttps%253A%252F%252Ffci.health%252Fen%252Fresearch%252Fclinical-translation-programs%252F%7Ctitle%3AClinical%2520Translation%2520Programs%7C%7C%22%2C%22color%22%3A%22blue%22%7D%2C%7B%22line1%22%3A%22P1%22%2C%22line2%22%3A%22Proteomics%20%26%20Functional%20Genomics%22%2C%22text%22%3A%22The%20goal%20of%20Technology%20Platform%201%20is%20to%20find%20individual%20parameters%20that%20can%20improve%20the%20diagnosis%20of%20tumors%20or%20better%20predict%20the%20response%20to%20therapy.%20For%20example%2C%20the%20composition%20of%20all%20proteins%20in%20a%20cell%20can%20be%20qualitatively%20and%20quantitatively%20analyzed%20by%20means%20of%20mass%20spectrometry.%20The%20measured%20profile%20(%E2%80%9Cproteome%E2%80%9D)%20contains%20unique%20information%20%E2%80%93%20similar%20to%20a%20fingerprint%20%E2%80%93%20and%20by%20comparing%20tumor%20cells%20with%20healthy%20cells%20of%20the%20same%20patient%2C%20new%20prognostic%20and%20diagnostic%20criteria%20can%20be%20identified.%22%2C%22link%22%3A%22url%3Ahttps%253A%252F%252Ffci.health%252Fen%252Fresearch%252Fresearch-areas%252Fr1%252F%7C%7C%7C%22%2C%22color%22%3A%22gray%22%7D%2C%7B%22line1%22%3A%22P2%22%2C%22line2%22%3A%22Immuno-Oncology%22%2C%22text%22%3A%22Technology%20platform%202%20Immuno-Oncology%20uses%20the%20innovative%20cell%20type-specific%20gene%20transfer%20technologies%20available%20at%20FCI%20to%20develop%20new%20immunotherapeutic%20concepts.%20These%20include%20the%20genetic%20modification%20of%20T%20lymphocytes%20or%20natural%20killer%20cells%20(NKs)%20with%20chimeric%20antigen%20receptors%20(CARs)%20as%20well%20as%20the%20precise%20transfer%20of%20immunomodulatory%20agents%20into%20tumor%20tissue.%5CnThis%20is%20complemented%20by%20the%20Immunomonitoring%20Platform.%22%2C%22link%22%3A%22url%3Ahttps%253A%252F%252Ffci.health%252Fen%252Fresearch%252Fresearch-areas%252Frf2%252F%7Ctitle%3AR2%253A%2520Molecular%2520Mechanisms%2520of%2520Tumor%2520Pathogenesis%7C%7C%22%2C%22color%22%3A%22gray%22%7D%2C%7B%22line1%22%3A%22P3%22%2C%22line2%22%3A%22Tumor%20Models%22%2C%22text%22%3A%22The%20aim%20of%20Technology%20Platform%203%20Tumor%20Models%20is%20to%20develop%20new%20tumor%20models%20that%20can%20be%20used%20to%20better%20predict%20the%20clinical%20success%20of%20a%20compound%20identified%20in%20basic%20research%20in%20patients.%20This%20platform%20represents%20the%20essential%20link%20for%20the%20transfer%20of%20new%20therapeutic%20strategies%20into%20the%20clinic.%20%22%2C%22link%22%3A%22url%3Ahttps%253A%252F%252Ffci.health%252Fen%252Fresearch%252Fresearch-areas%252Fr3%252F%7C%7C%7C%22%2C%22color%22%3A%22gray%22%7D%2C%7B%22line1%22%3A%22P4%22%2C%22line2%22%3A%22Drug%20Development%22%2C%22text%22%3A%22The%20goal%20of%20the%20Technology%20Platform%204%20is%20to%20develop%20new%20therapeutic%20approaches%20and%20to%20advance%20them%20to%20the%20development%20of%20new%20drugs.%20The%20extensive%20chemical%2C%20pharmaceutical%20and%20structural%20biology%20expertise%20at%20Goethe%20University%20in%20Frankfurt%20makes%20it%20possible%20to%20develop%20and%20optimize%20new%20drug%20candidates%20against%20validated%20target%20structures%3B%20innovative%20biologicals%20and%20cell%20therapeutics%20are%20developed%20at%20Georg-Speyer-Haus%20and%20the%20Paul-Ehrlich-Institut.%22%2C%22link%22%3A%22url%3Ahttps%253A%252F%252Ffci.health%252Fen%252Fresearch%252Fresearch-areas%252Fr4%252F%7C%7C%7C%22%2C%22color%22%3A%22gray%22%7D%2C%7B%22line1%22%3A%22P5%22%2C%22line2%22%3A%22%20Clinical%20Translation%20%26%20Biobank%22%2C%22text%22%3A%22The%20integration%20of%20clinical%20trials%20into%20the%20FCI%20is%20essential%20as%20an%20endpoint%20for%20drug%20development%20and%20a%20starting%20point%20for%20the%20investigation%20of%20response%20and%20resistance%20mechanisms.%20The%20goal%20is%20to%20initiate%20such%20studies%20in%20close%20collaboration%20with%20the%20University%20Center%20for%20Tumor%20Diseases%20(UCT).%20The%20UCT%20Frankfurt%20has%20continuously%20worked%20on%20the%20expansion%20of%20a%20comprehensive%20clinical%20research%20unit%2C%20which%20will%20be%20fully%20available%20to%20the%20FCI.%20This%20ensures%20the%20practical%20implementation%20of%20early%20translational%20studies%20at%20the%20FCI%20site.%22%2C%22link%22%3A%22url%3Ahttps%253A%252F%252Ffci.health%252Fen%252Fresearch%252Fresearch-areas%252Fr5%252F%7C%7C%7C%22%2C%22color%22%3A%22gray%22%7D%2C%7B%22line1%22%3A%22Discovery%20%26%20Development%22%2C%22text%22%3A%22The%20primary%20objective%20of%20this%20program%20is%20to%20address%20excellent%20hypotheses%20on%20basic%20biological%20mechanisms%20of%20tumorigenesis%2C%20progression%2C%20diagnosis%2C%20and%20therapy.%20%22%2C%22link%22%3A%22url%3Ahttps%253A%252F%252Ffci.health%252Fen%252Fresearch%252Fdiscovery-development%252F%7C%7C%7C%22%2C%22color%22%3A%22orange-light%22%7D%5D”][\/vc_column][\/vc_row][vc_row full_width=”stretch_row” dhsv_background_color=”bg_gray-light” dhsv_padding_top=”vc-padding-top-medium” dhsv_padding_bottom=”vc-padding-bottom-medium”][vc_column][dhsv_vc_anker type=”point” title=”Platforms” id=”forschungsbereiche”][dhsv_vc_expandtext activeimage=”true” image=”192″ mobileimage=”303″ link=”url:https%3A%2F%2Ffci.health%2Fen%2Fresearch%2Fresearch-areas%2Fp1-proteomics-functional-genomics%2F”]<\/p>\n

P 1<\/p>\n

PROTEOMICS & FUNCTIONAL GENOMICS<\/h2>\n

 <\/p>\n

Tumor cells are changing at tremendous speed. On the one hand, this property promotes their rampant growth and the development of resistance to therapy, on the other hand, it results in no tumor being the same as the other, making reliable prognoses for individual patients often difficult.<\/p>\n

The goal of Technology Platform 1 is to find individual parameters that can improve the diagnosis of tumors or better predict the response to therapy. For example, the composition of all proteins in a cell can be qualitatively and quantitatively analyzed by means of mass spectrometry. The measured profile (\u201cproteome\u201d) contains unique information \u2013 similar to a fingerprint \u2013 and by comparing tumor cells with healthy cells of the same patient, new prognostic and diagnostic criteria can be identified.[\/dhsv_vc_expandtext][vc_empty_space height=”120px”][dhsv_vc_expandtext activeimage=”true” inverttriangle=”true” image=”193″ mobileimage=”305″ link=”url:https%3A%2F%2Ffci.health%2Fen%2Fresearch%2Fresearch-areas%2Fp2-immuno-oncology%2F|title:P2%3A%20Immuno-Oncology”]<\/p>\n

P2<\/p>\n

IMMUNO-ONCOLOGY<\/h2>\n

 <\/p>\n

The newly established immuno-oncology platform will use the innovative cell type-specific gene transfer technologies available at FCI to develop new immunotherapeutic concepts. These include the genetic modification of T lymphocytes or natural killer cells (NKs) with chimeric antigen receptors (CARs) as well as the precise transfer of immunomodulatory agents into tumor tissue.<\/p>\n

The necessary vector systems have been and are being developed within the FCI by the partner PEI. World-leading in the generation of so-called receptor-targeted vectors, CD4- and CD8-targeted lentiviral vectors have been generated, which can introduce therapeutic genes highly selectively with more than 99% precision into the respective subtypes of T- lymphocytes. This precise gene transfer not only works ex vivo in cultured cells, but also in vivo, in mouse models, the general feasibility of the concept could be demonstrated.[\/dhsv_vc_expandtext][vc_empty_space height=”120px”][dhsv_vc_expandtext activeimage=”true” image=”194″ mobileimage=”307″ link=”url:https%3A%2F%2Ffci.health%2Fen%2Fresearch%2Fresearch-areas%2Fp3-tumor-models%2F|title:P3%3A%20Tumor%20Models”]<\/p>\n

P3<\/p>\n

TUMOR MODELS<\/h2>\n

 <\/p>\n

This platform represents the essential link for the transfer of new therapeutic strategies into the clinic. Far too often, promising compounds fail in later clinical development. The lack of meaningful preclinical models is an important reason for this low success rate. The aim of Technology Platform 3 is therefore to develop new tumor models that can be used to better predict the clinical success of a compound identified in basic research in patients.<\/p>\n

Technology Platform 3 focuses primarily on the development and application of patient- derived tumor models (PDX), new techniques for cultivating tumor cells in three- dimensional structures (organoid cultures), and the use of relevant genetically defined mouse models. The close interaction with the biobank of the University Center for Tumor Diseases (UCT) enables early research on the effects to be expected in patients and to obtain decisive indications for further development.[\/dhsv_vc_expandtext][vc_empty_space height=”120px”][dhsv_vc_expandtext activeimage=”true” inverttriangle=”true” image=”195″ mobileimage=”309″ link=”url:https%3A%2F%2Ffci.health%2Fen%2Fresearch%2Fresearch-areas%2Fp4-drug-development%2F|title:P4%3A%20Drug%20Development”]<\/p>\n

P4<\/p>\n

DRUG DEVELOPMENT<\/h2>\n

 <\/p>\n

The goal of the Technology Platform 4 is to develop new therapeutic approaches and to advance them to the development of new drugs. The extensive chemical, pharmaceutical and structural biology expertise at Goethe University in Frankfurt makes it possible to develop and optimize new drug candidates against validated target structures; innovative “biologicals” and cell therapeutics are developed at Georg-Speyer-Haus and the Paul- Ehrlich-Institut in Langen, for which certified production areas are available at the Institute of Transfusion Medicine.<\/p>\n

Since 2017, Goethe University Frankfurt has also been one of the academic sites of the global Structural Genomics Consortium (SGC), a public-private open science partnership with the aim of accelerating drug development by exploiting previously untapped resources. The FCI will collaborate closely on drug discovery with the SGC site in Frankfurt, which has libraries of compounds for potential new applications as well as highly selective inhibitors.[\/dhsv_vc_expandtext][vc_empty_space height=”120px”][dhsv_vc_expandtext activeimage=”true” image=”196″ mobileimage=”311″ link=”url:https%3A%2F%2Ffci.health%2Fen%2Fresearch%2Fresearch-areas%2Fp5-clinical-translation-biobank%2F|title:P5%3A%20Clinical%20Translation%20%26%20Biobank”]<\/p>\n

P5<\/p>\n

CLINICAL TRANSLATION & BIOBANK<\/h2>\n

 <\/p>\n

The integration of clinical trials into the FCI is essential as an endpoint for drug development and a starting point for the investigation of response and resistance mechanisms. The goal is to initiate such studies in close collaboration with the University Center for Tumor Diseases (UCT). The UCT Frankfurt has continuously worked on the expansion of a comprehensive clinical research unit, which will be fully available to the FCI. This ensures the practical implementation of early translational studies at the FCI site.<\/p>\n

Of particular importance for the FCI are also the clinical scientists of the Technology Platform 5 Clinical Translation and Biobank, who are organized in multicenter study groups for therapy optimization. They assist the FCI project groups with questions of clinical relevance and cover a broad spectrum of indications (gastric, rectal, breast and lung carcinomas, brain tumors, acute lymphoid and myeloid leukemias, multiple myelomas, lymphomas).[\/dhsv_vc_expandtext][\/vc_column][\/vc_row][vc_row full_width=”stretch_row” content_placement=”middle” dhsv_background_color=”bg_gray”][vc_column offset=”vc_hidden-lg vc_hidden-md”][dhsv_vc_graphic graphic=”228″][\/vc_column][\/vc_row][vc_row full_width=”stretch_row” content_placement=”middle” dhsv_background_color=”bg_gray” dhsv_padding_top=”vc-padding-top-medium” dhsv_padding_bottom=”vc-padding-bottom-medium” dhsv_bgposition=”vc-bgposition-top-right” css=”.vc_custom_1537261227996{background-image: url(https:\/\/fci.health\/wp-content\/uploads\/FCI-Onepager-discoverydevelopment-gesamt.png?id=228) !important;}” el_class=”bgimage002″][vc_column offset=”vc_col-md-6″][dhsv_vc_anker type=”point” title=”Discovery & Development Program” id=”discovery-development-program”][dhsv_vc_expandtext link=”url:https%3A%2F%2Ffci.health%2Fen%2Fresearch%2Fdiscovery-development%2F|||”]<\/p>\n

Discovery & Development Program<\/span><\/p>\n

The primary objective of this program is to address excellent hypotheses on basic biological mechanisms of tumorigenesis, progression, diagnosis, and therapy. For example, the proposed projects elucidate the molecular mechanisms of applied or new therapies, define potential target structures in tumors, identify oncogenic mutations, or serve model and method development to expand the repertoire of diagnostic assays, innovative technologies, and preclinical models. In the medium to long term, these projects can lead to a disease-specific clinical translation program.
\nD&D projects are advertised annually internally and funded by the FCI in the sense of a start-up aid. They should always demonstrate a long-term perspective, which will allow them to attract additional research funding in the future.<\/span><\/p>\n

[\/dhsv_vc_expandtext][dhsv_vc_anker type=”end”][\/vc_column][vc_column offset=”vc_col-md-6″][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

[vc_row full_width=”stretch_row_content_no_spaces” dhsv_background_color=”bg_brand-primary” dhsv_overflow=”vc-overflow-visible”][vc_column el_id=”ueberuns”][dhsv_vc_slider image_right=”162″ image_middle=”161″ image_left=”160″ anchor=”1″][vc_column_text css_animation=”none”] Unique Environment Molecular Mechanisms [\/vc_column_text][vc_column_text] Precision Oncology Teamspirit [\/vc_column_text][\/dhsv_vc_slider][dhsv_vc_anker type=”nav”][\/vc_column][\/vc_row][vc_row el_class=”translateY100″][vc_column offset=”vc_col-md-4″][dhsv_vc_anker type=”point” title=”Clinical Translation Programs” id=”querschnittsprogramme”][\/vc_column][vc_column offset=”vc_col-md-7″][vc_column_text] Clinical Translation Programs\u00a0are the\u00a0Strategic Core\u00a0of FCI. [\/vc_column_text][\/vc_column][vc_column offset=”vc_col-md-1″][\/vc_column][\/vc_row][vc_row dhsv_margin_top=”vc-margin-top-medium” dhsv_margin_bottom=”vc-margin-bottom-medium”][vc_column][dhsv_vc_forschungsbereiche headtitle=”Research in FCI” elements=”%5B%7B%22line1%22%3A%22Clinical%20Translation%20Programs%22%2C%22line2%22%3A%22Strategic%20Core%20of%20FCI%22%2C%22text%22%3A%22Multidisciplinary%20teams%20consisting%20of%20clinicians%2C%20tumor%20biologists%2C%20biochemists%2C%20chemists%20and%20bioinformaticians%20work%20together%20in%20these%20interdisciplinary%20research%20projects.%20The%20teams%20rely%20on%20the%20technology%20platforms%20provided%20by%20the%20five%20research%20areas.%20%22%2C%22link%22%3A%22url%3Ahttps%253A%252F%252Ffci.health%252Fen%252Fresearch%252Fclinical-translation-programs%252F%7Ctitle%3AClinical%2520Translation%2520Programs%7C%7C%22%2C%22color%22%3A%22blue%22%7D%2C%7B%22line1%22%3A%22P1%22%2C%22line2%22%3A%22Proteomics%20%26%20Functional%20Genomics%22%2C%22text%22%3A%22The%20goal%20of%20Technology%20Platform%201%20is%20to%20find%20individual%20parameters%20that%20can%20improve%20the%20diagnosis%20of%20tumors%20or%20better%20predict%20the%20response%20to%20therapy.%20For%20example%2C%20the%20composition%20of%20all%20proteins%20in%20a%20cell%20can%20be%20qualitatively%20and%20quantitatively%20analyzed%20by%20means%20of%20mass%20spectrometry.%20The%20measured%20profile%20(%E2%80%9Cproteome%E2%80%9D)%20contains%20unique%20information%20%E2%80%93%20similar%20to%20a%20fingerprint%20%E2%80%93%20and%20by%20comparing%20tumor%20cells%20with%20healthy%20cells%20of%20the%20same%20patient%2C%20new%20prognostic%20and%20diagnostic%20criteria%20can%20be%20identified.%22%2C%22link%22%3A%22url%3Ahttps%253A%252F%252Ffci.health%252Fen%252Fresearch%252Fresearch-areas%252Fr1%252F%7C%7C%7C%22%2C%22color%22%3A%22gray%22%7D%2C%7B%22line1%22%3A%22P2%22%2C%22line2%22%3A%22Immuno-Oncology%22%2C%22text%22%3A%22Technology%20platform%202%20Immuno-Oncology%20uses%20the%20innovative%20cell%20type-specific%20gene%20transfer%20technologies%20available%20at%20FCI%20to%20develop%20new%20immunotherapeutic%20concepts.%20These%20include%20the%20genetic%20modification%20of%20T%20lymphocytes%20or%20natural%20killer%20cells%20(NKs)%20with%20chimeric%20antigen%20receptors%20(CARs)%20as%20well%20as%20the%20precise%20transfer%20of%20immunomodulatory%20agents%20into%20tumor%20tissue.%5CnThis%20is%20complemented%20by%20the%20Immunomonitoring%20Platform.%22%2C%22link%22%3A%22url%3Ahttps%253A%252F%252Ffci.health%252Fen%252Fresearch%252Fresearch-areas%252Frf2%252F%7Ctitle%3AR2%253A%2520Molecular%2520Mechanisms%2520of%2520Tumor%2520Pathogenesis%7C%7C%22%2C%22color%22%3A%22gray%22%7D%2C%7B%22line1%22%3A%22P3%22%2C%22line2%22%3A%22Tumor%20Models%22%2C%22text%22%3A%22The%20aim%20of%20Technology%20Platform%203%20Tumor%20Models%20is%20to%20develop%20new%20tumor%20models%20that%20can%20be%20used%20to%20better%20predict%20the%20clinical%20success%20of%20a%20compound%20identified%20in%20basic%20research%20in%20patients.%20This%20platform%20represents%20the%20essential%20link%20for%20the%20transfer%20of%20new%20therapeutic%20strategies%20into%20the%20clinic.%20%22%2C%22link%22%3A%22url%3Ahttps%253A%252F%252Ffci.health%252Fen%252Fresearch%252Fresearch-areas%252Fr3%252F%7C%7C%7C%22%2C%22color%22%3A%22gray%22%7D%2C%7B%22line1%22%3A%22P4%22%2C%22line2%22%3A%22Drug%20Development%22%2C%22text%22%3A%22The%20goal%20of%20the%20Technology%20Platform%204%20is%20to%20develop%20new%20therapeutic%20approaches%20and%20to%20advance%20them%20to%20the%20development%20of%20new%20drugs.%20The%20extensive%20chemical%2C%20pharmaceutical%20and%20structural%20biology%20expertise%20at%20Goethe%20University%20in%20Frankfurt%20makes%20it%20possible%20to%20develop%20and%20optimize%20new%20drug%20candidates%20against%20validated%20target%20structures%3B%20innovative%20biologicals%20and%20cell%20therapeutics%20are%20developed%20at%20Georg-Speyer-Haus%20and%20the%20Paul-Ehrlich-Institut.%22%2C%22link%22%3A%22url%3Ahttps%253A%252F%252Ffci.health%252Fen%252Fresearch%252Fresearch-areas%252Fr4%252F%7C%7C%7C%22%2C%22color%22%3A%22gray%22%7D%2C%7B%22line1%22%3A%22P5%22%2C%22line2%22%3A%22%20Clinical%20Translation%20%26%20Biobank%22%2C%22text%22%3A%22The%20integration%20of%20clinical%20trials%20into%20the%20FCI%20is%20essential%20as%20an%20endpoint%20for%20drug%20development%20and%20a%20starting%20point%20for%20the%20investigation%20of%20response%20and%20resistance%20mechanisms.%20The%20goal%20is%20to%20initiate%20such%20studies%20in%20close%20collaboration%20with%20the%20University%20Center%20for%20Tumor%20Diseases%20(UCT).%20The%20UCT%20Frankfurt%20has%20continuously%20worked%20on%20the%20expansion%20of%20a%20comprehensive%20clinical%20research%20unit%2C%20which%20will%20be%20fully%20available%20to%20the%20FCI.%20This%20ensures%20the%20practical%20implementation%20of%20early%20translational%20studies%20at%20the%20FCI%20site.%22%2C%22link%22%3A%22url%3Ahttps%253A%252F%252Ffci.health%252Fen%252Fresearch%252Fresearch-areas%252Fr5%252F%7C%7C%7C%22%2C%22color%22%3A%22gray%22%7D%2C%7B%22line1%22%3A%22Discovery%20%26%20Development%22%2C%22text%22%3A%22The%20primary%20objective%20of%20this%20program%20is%20to%20address%20excellent%20hypotheses%20on%20basic%20biological%20mechanisms%20of%20tumorigenesis%2C%20progression%2C%20diagnosis%2C%20and%20therapy.%20%22%2C%22link%22%3A%22url%3Ahttps%253A%252F%252Ffci.health%252Fen%252Fresearch%252Fdiscovery-development%252F%7C%7C%7C%22%2C%22color%22%3A%22orange-light%22%7D%5D”][\/vc_column][\/vc_row][vc_row full_width=”stretch_row” dhsv_background_color=”bg_gray-light” dhsv_padding_top=”vc-padding-top-medium” dhsv_padding_bottom=”vc-padding-bottom-medium”][vc_column][dhsv_vc_anker type=”point” title=”Platforms” id=”forschungsbereiche”][dhsv_vc_expandtext activeimage=”true” image=”192″ mobileimage=”303″ link=”url:https%3A%2F%2Ffci.health%2Fen%2Fresearch%2Fresearch-areas%2Fp1-proteomics-functional-genomics%2F”] P 1 ganzen Artikel lesen…<\/a><\/p>\n","protected":false},"author":3,"featured_media":0,"parent":0,"menu_order":9,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-561","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\nPlatform • Frankfurt Cancer Institute<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fci.health\/en\/platform\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Platform • Frankfurt Cancer Institute\" \/>\n<meta property=\"og:description\" content=\"[vc_row full_width=”stretch_row_content_no_spaces” dhsv_background_color=”bg_brand-primary” dhsv_overflow=”vc-overflow-visible”][vc_column el_id=”ueberuns”][dhsv_vc_slider image_right=”162″ image_middle=”161″ image_left=”160″ anchor=”1″][vc_column_text css_animation=”none”] Unique Environment Molecular Mechanisms [\/vc_column_text][vc_column_text] Precision Oncology Teamspirit [\/vc_column_text][\/dhsv_vc_slider][dhsv_vc_anker type=”nav”][\/vc_column][\/vc_row][vc_row el_class=”translateY100″][vc_column offset=”vc_col-md-4″][dhsv_vc_anker type=”point” title=”Clinical Translation Programs” id=”querschnittsprogramme”][\/vc_column][vc_column offset=”vc_col-md-7″][vc_column_text] Clinical Translation Programs\u00a0are the\u00a0Strategic Core\u00a0of FCI. [\/vc_column_text][\/vc_column][vc_column offset=”vc_col-md-1″][\/vc_column][\/vc_row][vc_row dhsv_margin_top=”vc-margin-top-medium” dhsv_margin_bottom=”vc-margin-bottom-medium”][vc_column][dhsv_vc_forschungsbereiche headtitle=”Research in FCI” elements=”%5B%7B%22line1%22%3A%22Clinical%20Translation%20Programs%22%2C%22line2%22%3A%22Strategic%20Core%20of%20FCI%22%2C%22text%22%3A%22Multidisciplinary%20teams%20consisting%20of%20clinicians%2C%20tumor%20biologists%2C%20biochemists%2C%20chemists%20and%20bioinformaticians%20work%20together%20in%20these%20interdisciplinary%20research%20projects.%20The%20teams%20rely%20on%20the%20technology%20platforms%20provided%20by%20the%20five%20research%20areas.%20%22%2C%22link%22%3A%22url%3Ahttps%253A%252F%252Ffci.health%252Fen%252Fresearch%252Fclinical-translation-programs%252F%7Ctitle%3AClinical%2520Translation%2520Programs%7C%7C%22%2C%22color%22%3A%22blue%22%7D%2C%7B%22line1%22%3A%22P1%22%2C%22line2%22%3A%22Proteomics%20%26%20Functional%20Genomics%22%2C%22text%22%3A%22The%20goal%20of%20Technology%20Platform%201%20is%20to%20find%20individual%20parameters%20that%20can%20improve%20the%20diagnosis%20of%20tumors%20or%20better%20predict%20the%20response%20to%20therapy.%20For%20example%2C%20the%20composition%20of%20all%20proteins%20in%20a%20cell%20can%20be%20qualitatively%20and%20quantitatively%20analyzed%20by%20means%20of%20mass%20spectrometry.%20The%20measured%20profile%20(%E2%80%9Cproteome%E2%80%9D)%20contains%20unique%20information%20%E2%80%93%20similar%20to%20a%20fingerprint%20%E2%80%93%20and%20by%20comparing%20tumor%20cells%20with%20healthy%20cells%20of%20the%20same%20patient%2C%20new%20prognostic%20and%20diagnostic%20criteria%20can%20be%20identified.%22%2C%22link%22%3A%22url%3Ahttps%253A%252F%252Ffci.health%252Fen%252Fresearch%252Fresearch-areas%252Fr1%252F%7C%7C%7C%22%2C%22color%22%3A%22gray%22%7D%2C%7B%22line1%22%3A%22P2%22%2C%22line2%22%3A%22Immuno-Oncology%22%2C%22text%22%3A%22Technology%20platform%202%20Immuno-Oncology%20uses%20the%20innovative%20cell%20type-specific%20gene%20transfer%20technologies%20available%20at%20FCI%20to%20develop%20new%20immunotherapeutic%20concepts.%20These%20include%20the%20genetic%20modification%20of%20T%20lymphocytes%20or%20natural%20killer%20cells%20(NKs)%20with%20chimeric%20antigen%20receptors%20(CARs)%20as%20well%20as%20the%20precise%20transfer%20of%20immunomodulatory%20agents%20into%20tumor%20tissue.%5CnThis%20is%20complemented%20by%20the%20Immunomonitoring%20Platform.%22%2C%22link%22%3A%22url%3Ahttps%253A%252F%252Ffci.health%252Fen%252Fresearch%252Fresearch-areas%252Frf2%252F%7Ctitle%3AR2%253A%2520Molecular%2520Mechanisms%2520of%2520Tumor%2520Pathogenesis%7C%7C%22%2C%22color%22%3A%22gray%22%7D%2C%7B%22line1%22%3A%22P3%22%2C%22line2%22%3A%22Tumor%20Models%22%2C%22text%22%3A%22The%20aim%20of%20Technology%20Platform%203%20Tumor%20Models%20is%20to%20develop%20new%20tumor%20models%20that%20can%20be%20used%20to%20better%20predict%20the%20clinical%20success%20of%20a%20compound%20identified%20in%20basic%20research%20in%20patients.%20This%20platform%20represents%20the%20essential%20link%20for%20the%20transfer%20of%20new%20therapeutic%20strategies%20into%20the%20clinic.%20%22%2C%22link%22%3A%22url%3Ahttps%253A%252F%252Ffci.health%252Fen%252Fresearch%252Fresearch-areas%252Fr3%252F%7C%7C%7C%22%2C%22color%22%3A%22gray%22%7D%2C%7B%22line1%22%3A%22P4%22%2C%22line2%22%3A%22Drug%20Development%22%2C%22text%22%3A%22The%20goal%20of%20the%20Technology%20Platform%204%20is%20to%20develop%20new%20therapeutic%20approaches%20and%20to%20advance%20them%20to%20the%20development%20of%20new%20drugs.%20The%20extensive%20chemical%2C%20pharmaceutical%20and%20structural%20biology%20expertise%20at%20Goethe%20University%20in%20Frankfurt%20makes%20it%20possible%20to%20develop%20and%20optimize%20new%20drug%20candidates%20against%20validated%20target%20structures%3B%20innovative%20biologicals%20and%20cell%20therapeutics%20are%20developed%20at%20Georg-Speyer-Haus%20and%20the%20Paul-Ehrlich-Institut.%22%2C%22link%22%3A%22url%3Ahttps%253A%252F%252Ffci.health%252Fen%252Fresearch%252Fresearch-areas%252Fr4%252F%7C%7C%7C%22%2C%22color%22%3A%22gray%22%7D%2C%7B%22line1%22%3A%22P5%22%2C%22line2%22%3A%22%20Clinical%20Translation%20%26%20Biobank%22%2C%22text%22%3A%22The%20integration%20of%20clinical%20trials%20into%20the%20FCI%20is%20essential%20as%20an%20endpoint%20for%20drug%20development%20and%20a%20starting%20point%20for%20the%20investigation%20of%20response%20and%20resistance%20mechanisms.%20The%20goal%20is%20to%20initiate%20such%20studies%20in%20close%20collaboration%20with%20the%20University%20Center%20for%20Tumor%20Diseases%20(UCT).%20The%20UCT%20Frankfurt%20has%20continuously%20worked%20on%20the%20expansion%20of%20a%20comprehensive%20clinical%20research%20unit%2C%20which%20will%20be%20fully%20available%20to%20the%20FCI.%20This%20ensures%20the%20practical%20implementation%20of%20early%20translational%20studies%20at%20the%20FCI%20site.%22%2C%22link%22%3A%22url%3Ahttps%253A%252F%252Ffci.health%252Fen%252Fresearch%252Fresearch-areas%252Fr5%252F%7C%7C%7C%22%2C%22color%22%3A%22gray%22%7D%2C%7B%22line1%22%3A%22Discovery%20%26%20Development%22%2C%22text%22%3A%22The%20primary%20objective%20of%20this%20program%20is%20to%20address%20excellent%20hypotheses%20on%20basic%20biological%20mechanisms%20of%20tumorigenesis%2C%20progression%2C%20diagnosis%2C%20and%20therapy.%20%22%2C%22link%22%3A%22url%3Ahttps%253A%252F%252Ffci.health%252Fen%252Fresearch%252Fdiscovery-development%252F%7C%7C%7C%22%2C%22color%22%3A%22orange-light%22%7D%5D”][\/vc_column][\/vc_row][vc_row full_width=”stretch_row” dhsv_background_color=”bg_gray-light” dhsv_padding_top=”vc-padding-top-medium” dhsv_padding_bottom=”vc-padding-bottom-medium”][vc_column][dhsv_vc_anker type=”point” title=”Platforms” id=”forschungsbereiche”][dhsv_vc_expandtext activeimage=”true” image=”192″ mobileimage=”303″ link=”url:https%3A%2F%2Ffci.health%2Fen%2Fresearch%2Fresearch-areas%2Fp1-proteomics-functional-genomics%2F”] P 1 ganzen Artikel lesen...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fci.health\/en\/platform\/\" \/>\n<meta property=\"og:site_name\" content=\"Frankfurt Cancer Institute\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-28T10:32:59+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/fci.health\\\/en\\\/platform\\\/\",\"url\":\"https:\\\/\\\/fci.health\\\/en\\\/platform\\\/\",\"name\":\"Platform • Frankfurt Cancer Institute\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fci.health\\\/#website\"},\"datePublished\":\"2018-07-19T06:29:55+00:00\",\"dateModified\":\"2023-07-28T10:32:59+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/fci.health\\\/en\\\/platform\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/fci.health\\\/en\\\/platform\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/fci.health\\\/en\\\/platform\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/fci.health\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/fci.health\\\/#website\",\"url\":\"https:\\\/\\\/fci.health\\\/\",\"name\":\"Frankfurt Cancer Institute\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/fci.health\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Platform • Frankfurt Cancer Institute","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fci.health\/en\/platform\/","og_locale":"en_US","og_type":"article","og_title":"Platform • Frankfurt Cancer Institute","og_description":"[vc_row full_width=”stretch_row_content_no_spaces” dhsv_background_color=”bg_brand-primary” dhsv_overflow=”vc-overflow-visible”][vc_column el_id=”ueberuns”][dhsv_vc_slider image_right=”162″ image_middle=”161″ image_left=”160″ anchor=”1″][vc_column_text css_animation=”none”] Unique Environment Molecular Mechanisms [\/vc_column_text][vc_column_text] Precision Oncology Teamspirit [\/vc_column_text][\/dhsv_vc_slider][dhsv_vc_anker type=”nav”][\/vc_column][\/vc_row][vc_row el_class=”translateY100″][vc_column offset=”vc_col-md-4″][dhsv_vc_anker type=”point” title=”Clinical Translation Programs” id=”querschnittsprogramme”][\/vc_column][vc_column offset=”vc_col-md-7″][vc_column_text] Clinical Translation Programs\u00a0are the\u00a0Strategic Core\u00a0of FCI. [\/vc_column_text][\/vc_column][vc_column offset=”vc_col-md-1″][\/vc_column][\/vc_row][vc_row dhsv_margin_top=”vc-margin-top-medium” dhsv_margin_bottom=”vc-margin-bottom-medium”][vc_column][dhsv_vc_forschungsbereiche headtitle=”Research in FCI” elements=”%5B%7B%22line1%22%3A%22Clinical%20Translation%20Programs%22%2C%22line2%22%3A%22Strategic%20Core%20of%20FCI%22%2C%22text%22%3A%22Multidisciplinary%20teams%20consisting%20of%20clinicians%2C%20tumor%20biologists%2C%20biochemists%2C%20chemists%20and%20bioinformaticians%20work%20together%20in%20these%20interdisciplinary%20research%20projects.%20The%20teams%20rely%20on%20the%20technology%20platforms%20provided%20by%20the%20five%20research%20areas.%20%22%2C%22link%22%3A%22url%3Ahttps%253A%252F%252Ffci.health%252Fen%252Fresearch%252Fclinical-translation-programs%252F%7Ctitle%3AClinical%2520Translation%2520Programs%7C%7C%22%2C%22color%22%3A%22blue%22%7D%2C%7B%22line1%22%3A%22P1%22%2C%22line2%22%3A%22Proteomics%20%26%20Functional%20Genomics%22%2C%22text%22%3A%22The%20goal%20of%20Technology%20Platform%201%20is%20to%20find%20individual%20parameters%20that%20can%20improve%20the%20diagnosis%20of%20tumors%20or%20better%20predict%20the%20response%20to%20therapy.%20For%20example%2C%20the%20composition%20of%20all%20proteins%20in%20a%20cell%20can%20be%20qualitatively%20and%20quantitatively%20analyzed%20by%20means%20of%20mass%20spectrometry.%20The%20measured%20profile%20(%E2%80%9Cproteome%E2%80%9D)%20contains%20unique%20information%20%E2%80%93%20similar%20to%20a%20fingerprint%20%E2%80%93%20and%20by%20comparing%20tumor%20cells%20with%20healthy%20cells%20of%20the%20same%20patient%2C%20new%20prognostic%20and%20diagnostic%20criteria%20can%20be%20identified.%22%2C%22link%22%3A%22url%3Ahttps%253A%252F%252Ffci.health%252Fen%252Fresearch%252Fresearch-areas%252Fr1%252F%7C%7C%7C%22%2C%22color%22%3A%22gray%22%7D%2C%7B%22line1%22%3A%22P2%22%2C%22line2%22%3A%22Immuno-Oncology%22%2C%22text%22%3A%22Technology%20platform%202%20Immuno-Oncology%20uses%20the%20innovative%20cell%20type-specific%20gene%20transfer%20technologies%20available%20at%20FCI%20to%20develop%20new%20immunotherapeutic%20concepts.%20These%20include%20the%20genetic%20modification%20of%20T%20lymphocytes%20or%20natural%20killer%20cells%20(NKs)%20with%20chimeric%20antigen%20receptors%20(CARs)%20as%20well%20as%20the%20precise%20transfer%20of%20immunomodulatory%20agents%20into%20tumor%20tissue.%5CnThis%20is%20complemented%20by%20the%20Immunomonitoring%20Platform.%22%2C%22link%22%3A%22url%3Ahttps%253A%252F%252Ffci.health%252Fen%252Fresearch%252Fresearch-areas%252Frf2%252F%7Ctitle%3AR2%253A%2520Molecular%2520Mechanisms%2520of%2520Tumor%2520Pathogenesis%7C%7C%22%2C%22color%22%3A%22gray%22%7D%2C%7B%22line1%22%3A%22P3%22%2C%22line2%22%3A%22Tumor%20Models%22%2C%22text%22%3A%22The%20aim%20of%20Technology%20Platform%203%20Tumor%20Models%20is%20to%20develop%20new%20tumor%20models%20that%20can%20be%20used%20to%20better%20predict%20the%20clinical%20success%20of%20a%20compound%20identified%20in%20basic%20research%20in%20patients.%20This%20platform%20represents%20the%20essential%20link%20for%20the%20transfer%20of%20new%20therapeutic%20strategies%20into%20the%20clinic.%20%22%2C%22link%22%3A%22url%3Ahttps%253A%252F%252Ffci.health%252Fen%252Fresearch%252Fresearch-areas%252Fr3%252F%7C%7C%7C%22%2C%22color%22%3A%22gray%22%7D%2C%7B%22line1%22%3A%22P4%22%2C%22line2%22%3A%22Drug%20Development%22%2C%22text%22%3A%22The%20goal%20of%20the%20Technology%20Platform%204%20is%20to%20develop%20new%20therapeutic%20approaches%20and%20to%20advance%20them%20to%20the%20development%20of%20new%20drugs.%20The%20extensive%20chemical%2C%20pharmaceutical%20and%20structural%20biology%20expertise%20at%20Goethe%20University%20in%20Frankfurt%20makes%20it%20possible%20to%20develop%20and%20optimize%20new%20drug%20candidates%20against%20validated%20target%20structures%3B%20innovative%20biologicals%20and%20cell%20therapeutics%20are%20developed%20at%20Georg-Speyer-Haus%20and%20the%20Paul-Ehrlich-Institut.%22%2C%22link%22%3A%22url%3Ahttps%253A%252F%252Ffci.health%252Fen%252Fresearch%252Fresearch-areas%252Fr4%252F%7C%7C%7C%22%2C%22color%22%3A%22gray%22%7D%2C%7B%22line1%22%3A%22P5%22%2C%22line2%22%3A%22%20Clinical%20Translation%20%26%20Biobank%22%2C%22text%22%3A%22The%20integration%20of%20clinical%20trials%20into%20the%20FCI%20is%20essential%20as%20an%20endpoint%20for%20drug%20development%20and%20a%20starting%20point%20for%20the%20investigation%20of%20response%20and%20resistance%20mechanisms.%20The%20goal%20is%20to%20initiate%20such%20studies%20in%20close%20collaboration%20with%20the%20University%20Center%20for%20Tumor%20Diseases%20(UCT).%20The%20UCT%20Frankfurt%20has%20continuously%20worked%20on%20the%20expansion%20of%20a%20comprehensive%20clinical%20research%20unit%2C%20which%20will%20be%20fully%20available%20to%20the%20FCI.%20This%20ensures%20the%20practical%20implementation%20of%20early%20translational%20studies%20at%20the%20FCI%20site.%22%2C%22link%22%3A%22url%3Ahttps%253A%252F%252Ffci.health%252Fen%252Fresearch%252Fresearch-areas%252Fr5%252F%7C%7C%7C%22%2C%22color%22%3A%22gray%22%7D%2C%7B%22line1%22%3A%22Discovery%20%26%20Development%22%2C%22text%22%3A%22The%20primary%20objective%20of%20this%20program%20is%20to%20address%20excellent%20hypotheses%20on%20basic%20biological%20mechanisms%20of%20tumorigenesis%2C%20progression%2C%20diagnosis%2C%20and%20therapy.%20%22%2C%22link%22%3A%22url%3Ahttps%253A%252F%252Ffci.health%252Fen%252Fresearch%252Fdiscovery-development%252F%7C%7C%7C%22%2C%22color%22%3A%22orange-light%22%7D%5D”][\/vc_column][\/vc_row][vc_row full_width=”stretch_row” dhsv_background_color=”bg_gray-light” dhsv_padding_top=”vc-padding-top-medium” dhsv_padding_bottom=”vc-padding-bottom-medium”][vc_column][dhsv_vc_anker type=”point” title=”Platforms” id=”forschungsbereiche”][dhsv_vc_expandtext activeimage=”true” image=”192″ mobileimage=”303″ link=”url:https%3A%2F%2Ffci.health%2Fen%2Fresearch%2Fresearch-areas%2Fp1-proteomics-functional-genomics%2F”] P 1 ganzen Artikel lesen...","og_url":"https:\/\/fci.health\/en\/platform\/","og_site_name":"Frankfurt Cancer Institute","article_modified_time":"2023-07-28T10:32:59+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/fci.health\/en\/platform\/","url":"https:\/\/fci.health\/en\/platform\/","name":"Platform • Frankfurt Cancer Institute","isPartOf":{"@id":"https:\/\/fci.health\/#website"},"datePublished":"2018-07-19T06:29:55+00:00","dateModified":"2023-07-28T10:32:59+00:00","breadcrumb":{"@id":"https:\/\/fci.health\/en\/platform\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fci.health\/en\/platform\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/fci.health\/en\/platform\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/fci.health\/en\/"},{"@type":"ListItem","position":2,"name":"Platform"}]},{"@type":"WebSite","@id":"https:\/\/fci.health\/#website","url":"https:\/\/fci.health\/","name":"Frankfurt Cancer Institute","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fci.health\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/fci.health\/en\/wp-json\/wp\/v2\/pages\/561","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fci.health\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/fci.health\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/fci.health\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/fci.health\/en\/wp-json\/wp\/v2\/comments?post=561"}],"version-history":[{"count":5,"href":"https:\/\/fci.health\/en\/wp-json\/wp\/v2\/pages\/561\/revisions"}],"predecessor-version":[{"id":3573,"href":"https:\/\/fci.health\/en\/wp-json\/wp\/v2\/pages\/561\/revisions\/3573"}],"wp:attachment":[{"href":"https:\/\/fci.health\/en\/wp-json\/wp\/v2\/media?parent=561"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}